发作状态的临床特征和危险因素
Zhen Tian1, Yingchun Xu1, Rundong He1
1Tianjin Huanhu Hospital, Tianjin, China.
Brain and behavior
|August 22, 2025
概括
性状态 (CSE) 的严重程度与的持续时间有关. 修改后的状况严重度评分 (mSTESS) 预测患者的结果,指导关键的神经紧急护理.
科学领域:
- 神经学
- 紧急医疗
- 临床神经科学
背景情况:
- 状态 (CSE) 是一种急性神经疾病,需要立即评估.
- 了解CSE严重性和预后的风险因素对于有效的治疗策略至关重要.
- 目前对CSE风险因素的了解尚不完整,需要进一步的临床研究.
研究的目的:
- 分析CSE患者的临床特征.
- 确定影响CSE严重性的危险因素.
- 确定CSE预后的预测因素.
主要方法:
- 在2023年7月至2024年12月期间入院的104名CSE患者的回顾性分析.
- 根据严重程度的修改状态发症评分 (mSTESS) 和预后的格拉斯哥结局表 (GOS) 进行分类.
- 收集和分析了包括年龄,病因,持续时间和并发症在内的临床数据.
主要成果:
- 最常见的病因是中风 (43. 3%); 62. 5% 的患者患有严重的CSE (mSTESS ≥ 4).
- 发作持续时间显著影响了CSE的严重程度 (p < 0. 05).
- mSTESS评分是预后不佳的重要预测指标 (GOS ≤3) (p < 0. 05).
结论:
- 发作的持续时间是CSE严重性的独立风险因素.
- 在CSE患者中,mSTESS得分有效预测预后.
- 这些发现有助于管理神经紧急情况并改善患者的治疗结果.
相关概念视频
Seizures: Classification
586
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
586
Epilepsy and Seizures: Overview
277
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
277
Electroconvulsive Therapy
185
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
185
Aneurysm II: Clinical Manifestations and Diagnostic Studies
22
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
22
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
446
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
446
Antiepileptic Drugs: Potassium Channel Activators
274
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
274


